CN101835778A - Hdac抑制剂 - Google Patents

Hdac抑制剂 Download PDF

Info

Publication number
CN101835778A
CN101835778A CN200880112378A CN200880112378A CN101835778A CN 101835778 A CN101835778 A CN 101835778A CN 200880112378 A CN200880112378 A CN 200880112378A CN 200880112378 A CN200880112378 A CN 200880112378A CN 101835778 A CN101835778 A CN 101835778A
Authority
CN
China
Prior art keywords
dihydro
pyrrolo
compound
amino
quinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880112378A
Other languages
English (en)
Chinese (zh)
Inventor
M·A·阿什维尔
M·坦顿
N·D·纳姆德夫
J·M·拉皮埃尔
Y·刘
H·吴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arqule Inc
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of CN101835778A publication Critical patent/CN101835778A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200880112378A 2007-08-21 2008-08-21 Hdac抑制剂 Pending CN101835778A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96558407P 2007-08-21 2007-08-21
US60/965584 2007-08-21
PCT/US2008/073873 WO2009026446A2 (en) 2007-08-21 2008-08-21 Hdac inhibitors

Publications (1)

Publication Number Publication Date
CN101835778A true CN101835778A (zh) 2010-09-15

Family

ID=39828970

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880112378A Pending CN101835778A (zh) 2007-08-21 2008-08-21 Hdac抑制剂

Country Status (6)

Country Link
US (1) US20100261710A1 (https=)
EP (1) EP2190845A2 (https=)
JP (1) JP2010536876A (https=)
CN (1) CN101835778A (https=)
CA (1) CA2695452A1 (https=)
WO (1) WO2009026446A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119143740A (zh) * 2024-08-15 2024-12-17 杭州科兴生物化工有限公司 一种苯并噻吩类衍生物及其制备方法与应用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5688367B2 (ja) 2008-08-29 2015-03-25 トポターゲット・アクティーゼルスカブＴｏｐｏＴａｒｇｅｔ Ａ／Ｓ 新規なウレアおよびチオウレア誘導体
WO2011082266A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted heterocyclic compounds
US8546588B2 (en) 2010-02-26 2013-10-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2011106632A1 (en) * 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2013041407A1 (en) * 2011-09-19 2013-03-28 Cellzome Ag Hydroxamic acids as hdac6 inhibitors
JP6272773B2 (ja) * 2011-11-29 2018-01-31 ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． Ｈｄａｃ６阻害剤・抗腫瘍剤用複素環アミド化合物
WO2013154870A1 (en) 2012-04-10 2013-10-17 Annji Pharmaceutical Co., Ltd. Histone deacetylases (hdacs) inhibitors
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
US9878986B2 (en) 2013-04-29 2018-01-30 Chong Kun Dang Pharmaceutical Corp. Compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same
CN110621317B (zh) 2017-05-16 2023-05-12 安基生技新药股份有限公司 组蛋白去乙酰化酶（hdacs）抑制剂
CN113121527B (zh) * 2019-12-31 2024-09-06 上海辉启生物医药科技有限公司 三环类化合物及其用途
JP2023530788A (ja) 2020-06-08 2023-07-19 アンジー ファーマシューティカル カンパニー リミテッド 選択的ｈｄａｃ６阻害剤として有用なキナゾリン誘導体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1335898B1 (en) * 2000-09-29 2005-11-23 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
AR035417A1 (es) * 2001-01-27 2004-05-26 Hoffmann La Roche Derivados triciclicos de lactama y sultama, procesos para su elaboracion, medicamentos que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
EP1644323B1 (en) * 2003-07-07 2015-03-18 Georgetown University Histone deacetylase inhibitors and methods of use thereof
ITFI20050041A1 (it) * 2005-03-15 2006-09-16 Menarini Internat Operations Luxembourg Sa Idrossammati come inibitori dell'istone deacelitasi, loro preparazione e formulazioni farmaceutiche che li contengono

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119143740A (zh) * 2024-08-15 2024-12-17 杭州科兴生物化工有限公司 一种苯并噻吩类衍生物及其制备方法与应用

Also Published As

Publication number Publication date
WO2009026446A9 (en) 2010-03-11
CA2695452A1 (en) 2009-02-26
EP2190845A2 (en) 2010-06-02
WO2009026446A3 (en) 2009-09-11
JP2010536876A (ja) 2010-12-02
WO2009026446A8 (en) 2010-04-29
WO2009026446A2 (en) 2009-02-26
US20100261710A1 (en) 2010-10-14

Similar Documents

Publication Publication Date Title
CN101835778A (zh) Hdac抑制剂
Ahmed et al. Design, synthesis, molecular docking of new lipophilic acetamide derivatives affording potential anticancer and antimicrobial agents
JP4674231B2 (ja) ２量体小分子アポトーシス増強剤
JP5391351B2 (ja) ヘテロ二環式メタロプロテアーゼ阻害薬
ES2900243T3 (es) Compuestos de pirazolo[1,5-a]pirimidina sustituidos como inhibidores de trk quinasa
TW201625620A (zh) 作為蛋白去乙醯酶抑制劑及雙蛋白去乙醯酶蛋白激酶抑制劑之雜環氧肟酸及其使用方法
CN115768757B (zh) Cd206调节剂及其用途和制备方法
CN116354901B (zh) 一种噻唑烷二酮类化合物及其制备方法和应用
CN104220442B (zh) 烷化剂
JP7423655B2 (ja) キノリル含有化合物、医薬組成物およびその使用
KR20160018537A (ko) 베타-세크레타제(bace) 저해제로서의 4-아미노-6-페닐-5,6-디하이드로이미다조[1,5-a]피라진 유도체
Li et al. Novel pyrrolo [2, 1-c][1, 4] benzodiazepine-3, 11-dione (PBD) derivatives as selective HDAC6 inhibitors to suppress tumor metastasis and invasion in vitro and in vivo
WO2021115188A1 (zh) 一种组蛋白去乙酰化酶、蛋白酶体双靶点抑制剂及其制备方法和应用
JP2022504703A (ja) ピリミジン及びピラジンｈｄａｃ１、２阻害剤
JP4792128B2 (ja) 癌に対するｈｓｐ９０阻害剤としての５−（２−ヒドロキシフェニル）テトラゾール
JP2022502497A (ja) Ｈｄａｃ１、２の阻害剤
ES2983661T3 (es) Derivados de sulfonilurea y usos de los mismos
CN102180826A (zh) 含α氨基酸结构的组蛋白去乙酰化酶抑制剂及其用途
JP2011500603A5 (https=)
US11312680B2 (en) Method for treating a patient having a colon cancer
WO2018068357A1 (zh) 一类新型sirt2蛋白抑制剂及其在制药中的用途
CN110551048A (zh) 一类sirt2抑制剂、其制备方法及用途
CN104529933B (zh) 取代邻苯甲酰磺酰亚胺类组蛋白去乙酰化酶抑制剂及制备方法和应用
AU2016205137A1 (en) Furoquinolinediones as inhibitors of TDP2
Xu et al. Structural insights of sulfonamide-based NLRP3 inflammasome inhibitors: design, synthesis, and biological characterization

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100915